CTOs on the Move

U S Endoscopy

www.usendoscopy.com

 
Founded in 1991, US Endoscopy is a privately held, family-owned company specializing in device design and manufacturing of accessories for GI endoscopy. Marlin Younker, US Endoscopy Founder and Co-Chairman, is a respected pioneer in the industry
  • Number of Employees: 250-1000
  • Annual Revenue: $50-100 Million

Executives

Name Title Contact Details

Similar Companies

Echo Solution

Echo, a HealthStream Company, is a combination of two industry leading software development companies, HealthLine Systems and Sy.Med Development. Echo develops and supports a comprehensive solution set for healthcare provider credentialing, privileging, enrollment, referral, onboarding, and analytics. Echo is supported by an industry leading development and client services staff with significant combined experience in the healthcare industry.

Mission Athletecare

MISSION is the first and only line of athlete-engineered products designed to enhance performance in training and competition. Co-founded in 2009 by a premier group of world-class athletes including Serena Williams, Dwyane Wade, Sergio Garcia, David Wright, Reggie Bush and Mia Hamm, MISSION boasts more than 25 high-performance product innovations and is sold in nearly 20,000 stores across the U.S. MISSION works with its world-renowned athletes, doctors and scientists to engineer products that help athletes prepare, perform and rehab from training or competition.

Alquest

Alquest has supported numerous international trials and registrations for device clients. Alquest's consulting staff comes from the medical device industry. We've been there. More than half our clients return to us for repeat business. Several device

NeoMend

NeoMend is a Irvine, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Enanta

We are a research and development-focused biotechnology company that uses its robust chemistry-driven approach and drug discovery capabilities to create small molecule drugs for viral infections and liver diseases. We are discovering, and in some cases developing, novel inhibitors designed for use against the hepatitis C virus, or HCV. These inhibitors include members of the direct acting antiviral (DAA) inhibitor classes – protease (partnered with AbbVie), NS5A, and nucleotide polymerase – as well as a host targeted antiviral (HTA) inhibitor class targeted against cyclophilin. In addition, Enanta has a preclinical program in non-alcoholic steatohepatitis, or NASH, which is a condition that results in liver inflammation and damage caused by a buildup of fat in the liver. Enanta is headquartered in Watertown, Massachusetts.